摘要
目的探讨术前行新辅助治疗(包括新辅助放化疗和新辅助化疗)联合外科手术治疗中晚期食管癌的可行性和安全性。方法ⅢA-ⅢC期局部中晚期食管鳞癌患者11例(A组),术前完成多西他赛+顺铂方案的新辅助化疗,同期给予常规分割剂量放疗;然后行食管癌切除术。选择病情相当,单纯接受手术治疗的的20例患者(B组)作对照,比较两组的疗效。结果 A组手术时间、术中出血量和淋巴结转移枚数均少于B组[(233.6±19.9)min vs.(257.3±28.9)min、(160.9±36.4)ml vs.(216.5±56.4)ml和(1.3±0.9)枚vs.(2.3±1.4)枚](P<0.05)。结论新辅助治疗联合外科手术治疗中晚期食管癌安全可行,近期临床疗效确切。
Objective To investigate the feasibility and safety of preoperative neoadjuvant chemoradiotherapy followed by surgery in the treatment of advanced esophageal carcinoma .Methods Preoperative neoadjuvant chemoradiotherapy with dorseyhesai ＋ cisplatin scheme and conventional dose radiotherapy was performed in 11 patients （group A ） with clinical stage Ⅲ A-Ⅲ C esophageal squamous carcinoma ,which was followed by surgical resection .The results were compared to those of 20 matched patients（group B） ,who underwent surgery without preoperative neoadjuvant chemoradio-therapy .Results The operative time ,intraoperative blood loss and numbers of metastatic lymph nodes were less in group A than those in group B [（233.6 ± 19.9） min vs .（257.3 ± 28.9） min ,（160.9 ± 36.4） ml vs .（216.5 ± 56.4） ml and （1.3 ± 0.9） pieces vs .（2.3 ± 1.4） pieces]（P〈0 .05） .Conclusion Preoperative neoadjuvant chemoradiotherapy is feasible and safe in the treatment of advanced esophageal carcinoma with good short-term outcomes .
出处
《江苏医药》
CAS
2015年第8期889-891,共3页
Jiangsu Medical Journal
基金
江苏省卫生厅面上项目(2013EA13)
关键词
食管癌
新辅助放化疗
Esophageal carcinoma
Neoadjuvant chemoradiotherapy
